Dr. Siricilla's research is focused on identifying novel therapeutic agents to manage infection-induced preterm birth and protecting the fetus against in-utero inflammation. The approaches include a large-scale screening of a customized library of molecules targeting the druggable transcriptome associated with infection-induced inflammation leading to preterm birth.

Dr. Siricilla's doctoral work focused on the discovery of novel antibacterial molecules with molecular targets against problematic pathogens such as Mycobacterium tuberculosis and multidrug-resistant nosocomial pathogens. She joined the Herington Lab in 2017 as a postdoctoral fellow where Dr. Siricilla worked on projects entailing a phenotypic high-throughput screen of large compound libraries to identify novel small molecules and molecular targets that regulate uterine myometrial contractions with high selectivity. She has developed a combination high-throughput assay to identify synergistic drug combinations to improve their tocolytic efficacy and therapeutic index. She has identified a natural product, mundulone, and FDA-approved drugs with tocolytic efficacy in mono- and combination therapy with current tocolytics.